These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

351 related articles for article (PubMed ID: 30889383)

  • 21. Inhibition of poly(ADP-ribose) glycohydrolase (PARG) specifically kills BRCA2-deficient tumor cells.
    Fathers C; Drayton RM; Solovieva S; Bryant HE
    Cell Cycle; 2012 Mar; 11(5):990-7. PubMed ID: 22333589
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeting DNA repair and replication stress in the treatment of ovarian cancer.
    Murai J
    Int J Clin Oncol; 2017 Aug; 22(4):619-628. PubMed ID: 28643177
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Selective small molecule inhibition of poly(ADP-ribose) glycohydrolase (PARG).
    Finch KE; Knezevic CE; Nottbohm AC; Partlow KC; Hergenrother PJ
    ACS Chem Biol; 2012 Mar; 7(3):563-70. PubMed ID: 22220926
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Poly(ADP-ribose) glycohydrolase mediates oxidative and excitotoxic neuronal death.
    Ying W; Sevigny MB; Chen Y; Swanson RA
    Proc Natl Acad Sci U S A; 2001 Oct; 98(21):12227-32. PubMed ID: 11593040
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Deletion of the nuclear isoform of poly(ADP-ribose) glycohydrolase (PARG) reveals its function in DNA repair, genomic stability and tumorigenesis.
    Min W; Cortes U; Herceg Z; Tong WM; Wang ZQ
    Carcinogenesis; 2010 Dec; 31(12):2058-65. PubMed ID: 20926829
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A nonradiometric, high-throughput assay for poly(ADP-ribose) glycohydrolase (PARG): application to inhibitor identification and evaluation.
    Putt KS; Hergenrother PJ
    Anal Biochem; 2004 Oct; 333(2):256-64. PubMed ID: 15450800
    [TBL] [Abstract][Full Text] [Related]  

  • 27. PARP Inhibition Increases the Reliance on ATR/CHK1 Checkpoint Signaling Leading to Synthetic Lethality-An Alternative Treatment Strategy for Epithelial Ovarian Cancer Cells Independent from HR Effectiveness.
    Gralewska P; Gajek A; Marczak A; Mikuła M; Ostrowski J; Śliwińska A; Rogalska A
    Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33352723
    [TBL] [Abstract][Full Text] [Related]  

  • 28. New Insights into the Roles of NAD+-Poly(ADP-ribose) Metabolism and Poly(ADP-ribose) Glycohydrolase.
    Tanuma S; Sato A; Oyama T; Yoshimori A; Abe H; Uchiumi F
    Curr Protein Pept Sci; 2016; 17(7):668-682. PubMed ID: 27817743
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inhibition of Poly ADP-Ribose Glycohydrolase Sensitizes Ovarian Cancer Cells to Poly ADP-Ribose Polymerase Inhibitors and Platinum Agents.
    Matanes E; López-Ozuna VM; Octeau D; Baloch T; Racovitan F; Dhillon AK; Kessous R; Raban O; Kogan L; Salvador S; Lau S; Gotlieb WH; Yasmeen A
    Front Oncol; 2021; 11():745981. PubMed ID: 34778062
    [TBL] [Abstract][Full Text] [Related]  

  • 30. PARG is dispensable for recovery from transient replicative stress but required to prevent detrimental accumulation of poly(ADP-ribose) upon prolonged replicative stress.
    Illuzzi G; Fouquerel E; Amé JC; Noll A; Rehmet K; Nasheuer HP; Dantzer F; Schreiber V
    Nucleic Acids Res; 2014 Jul; 42(12):7776-92. PubMed ID: 24906880
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Silencing of poly(ADP-ribose) glycohydrolase sensitizes lung cancer cells to radiation through the abrogation of DNA damage checkpoint.
    Nakadate Y; Kodera Y; Kitamura Y; Tachibana T; Tamura T; Koizumi F
    Biochem Biophys Res Commun; 2013 Nov; 441(4):793-8. PubMed ID: 24211580
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Design and synthesis of phenolic hydrazide hydrazones as potent poly(ADP-ribose) glycohydrolase (PARG) inhibitors.
    Islam R; Koizumi F; Kodera Y; Inoue K; Okawara T; Masutani M
    Bioorg Med Chem Lett; 2014 Aug; 24(16):3802-6. PubMed ID: 25042255
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Global analysis of transcriptional regulation by poly(ADP-ribose) polymerase-1 and poly(ADP-ribose) glycohydrolase in MCF-7 human breast cancer cells.
    Frizzell KM; Gamble MJ; Berrocal JG; Zhang T; Krishnakumar R; Cen Y; Sauve AA; Kraus WL
    J Biol Chem; 2009 Dec; 284(49):33926-38. PubMed ID: 19812418
    [TBL] [Abstract][Full Text] [Related]  

  • 34. ADP-ribosylome analysis reveals homogeneous DNA-damage-induced serine ADP-ribosylation across wild-type and BRCA-mutant breast cancer cell lines.
    Anagho HA; Mullari M; Prósz AG; Buch-Larsen SC; Cho H; Locard-Paulet M; Szallasi Z; Nielsen ML
    Cell Rep; 2024 Jul; 43(7):114433. PubMed ID: 38985679
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Poly (ADP-Ribose) Polymerases (PARPs) and PARP Inhibitor-Targeted Therapeutics.
    Li N; Wang Y; Deng W; Lin SH
    Anticancer Agents Med Chem; 2019; 19(2):206-212. PubMed ID: 30417796
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combined inhibition of PI3K and PARP is effective in the treatment of ovarian cancer cells with wild-type PIK3CA genes.
    Wang D; Li C; Zhang Y; Wang M; Jiang N; Xiang L; Li T; Roberts TM; Zhao JJ; Cheng H; Liu P
    Gynecol Oncol; 2016 Sep; 142(3):548-56. PubMed ID: 27426307
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Role of poly(ADP-ribose) glycohydrolase (PARG) in shock, ischemia and reperfusion.
    Cuzzocrea S; Wang ZQ
    Pharmacol Res; 2005 Jul; 52(1):100-8. PubMed ID: 15911338
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Influence of PARP, ATR, CHK1 Inhibitors on Premature Mitotic Entry and Genomic Instability in High-Grade Serous
    Gralewska P; Gajek A; Rybaczek D; Marczak A; Rogalska A
    Cells; 2022 Jun; 11(12):. PubMed ID: 35741017
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Rad51 Degradation: Role in Oncolytic Virus-Poly(ADP-Ribose) Polymerase Inhibitor Combination Therapy in Glioblastoma.
    Ning J; Wakimoto H; Peters C; Martuza RL; Rabkin SD
    J Natl Cancer Inst; 2017 Mar; 109(3):1-13. PubMed ID: 28376211
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Molecular Mechanisms of Actions, Effects, and Clinical Implications of PARP Inhibitors in Epithelial Ovarian Cancers: A Systematic Review.
    Lau CH; Seow KM; Chen KH
    Int J Mol Sci; 2022 Jul; 23(15):. PubMed ID: 35897700
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.